IMDX
Insight Molecular Diagnostics Inc.
$4.82
+0.36 (+8.07%)
At close · Jul 15
Market Cap
$152.09M
Shares
32,290,167
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.82
Open$4.49
Day$4.49–4.89
52W$2.33–8.51
Avg vol 30d274K
Short int1.0M · 3.1% float · 4.3d
Short vol49%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.7 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
−13%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
40%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−26%
trailing
YTD return
−36%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Distributing
2 of 41 funds reported for Jun 30 · net -64.9K sh shares
Insider flow
Accumulating
Net +$2.3M over 90 days · 0% sells
Short interest
Falling
3.12% of float · ▼ -12.2% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
41 holders — near 3-yr high, broad support
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
+116%
Y/Y
Gross margin
57%
expanding
EPS growth
+65%
Y/Y
Free cash flow
$-25.4M
Balance sheet
$9.7M
net cash
Quant / Vol
risk profile
Volatility
106%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
11.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Q2 2026
Revenue
Initiated
$250,000
prior qtr $32,000
midpoint +681.3% QoQ
back half of the year
Cash burn
Initiated
$6M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
40%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Distributing
2 of 41 funds reported for Jun 30 · net -64.9K sh shares
Insider flow
Accumulating
Net +$2.3M over 90 days · 0% sells
Short interest
Falling
3.12% of float · ▼ -12.2% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
41 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $5 · 40%
52-wk high $9
vs 200-day avg -11%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Medicare reimbursement rate for GraftAssure Core | $27.53 | Q1 2026 call | — |
| U.S. transplant centers expressed interest in registry | 34 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMDX
this stock
Insight Molecular Diagnostics Inc.
|
$152.09M | -35.7% | +25.1% | — | 3.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$199.75B | -7.5% | +0.4% | 29.6 | 1.4% |
|
DHR
Danaher Corp /De/
|
$145.10B | -11.9% | +8.5% | 39.6 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$45.55B | -17.7% | +10.4% | 42.5 | 2.5% |
|
NTRA
Natera, Inc.
|
$39.56B | +21.1% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMDX | +0.6% | -15.4% | -26.0% | -18.3% | -35.7% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -0.6% | -15.3% | -36.1% | -19.4% | -46.4% |